SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+18.21%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$636M
AUM Growth
+$241M
(+61%)
Cap. Flow
+$141M
Cap. Flow
% of AUM
22.24%
Top 10 Holdings %
Top 10 Hldgs %
53.71%
Holding
77
New
26
Increased
8
Reduced
17
Closed
9
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$48.3M |
| 2 |
Zimmer Biomet
ZBH
|
+$36.6M |
| 3 |
Organon & Co
OGN
|
+$27M |
| 4 |
Icon
ICLR
|
+$22.7M |
| 5 |
Waystar Holding Corp
WAY
|
+$21.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celcuity
CELC
|
+$25.4M |
| 2 |
Disc Medicine
IRON
|
+$19.2M |
| 3 |
Alkermes
ALKS
|
+$17.4M |
| 4 |
Merck
MRK
|
+$14.9M |
| 5 |
Henry Schein
HSIC
|
+$14.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.1% |
| 2 | Industrials | 6.79% |
| 3 | Miscellaneous | 5.13% |
| 4 | Consumer Staples | 3.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Celcuity
CELC
$2.93B
| $47.6M | 7.48% |
477,067
-309,459
| -39% | -$25.4M |
2025 Q3
1 quarter
|
|
|
2
Cigna
CI
$76.5B
| $47.4M | 7.46% |
+172,203
| New | +$48.3M |
2025 Q4
0 quarters
|
|
3
Sanofi
SNY
$95.3B
| $47.1M | 7.41% |
971,686
+408,983
| +73% | +$20.3M |
2025 Q2
2 quarters
|
|
4
Maximus
MMS
$3.02B
| $43.2M | 6.79% |
500,304
-57,311
| -10% | -$4.9M |
2024 Q3
5 quarters
|
|
|
5
Zimmer Biomet
ZBH
$17.5B
| $34.7M | 5.45% |
+385,642
| New | +$36.6M |
2025 Q4
0 quarters
|
|
6
PUT
Rhythm Pharmaceuticals
RYTM
$5.97B
| $28.4M | 4.47% |
+265,700
| New | +$28.2M |
2025 Q4
0 quarters
|
|
7
Kenvue
KVUE
$34.6B
| $25.3M | 3.98% |
1,465,442
+621,442
| +74% | +$10.2M |
2025 Q3
1 quarter
|
|
|
8
Organon & Co
OGN
$3.61B
| $24.5M | 3.86% |
+3,421,765
| New | +$27M |
2025 Q4
0 quarters
|
|
|
9
Icon
ICLR
$13B
| $23.2M | 3.65% |
+127,202
| New | +$22.7M |
2025 Q4
0 quarters
|
|
|
10
Waystar Holding Corp
WAY
$5.15B
| $20.1M | 3.16% |
+613,725
| New | +$21.9M |
2025 Q4
0 quarters
|
|
11
LivaNova
LIVN
$4.19B
| $19.8M | 3.12% |
+322,382
| New | +$18.4M |
2025 Q4
0 quarters
|
|
12
Dianthus Therapeutics
DNTH
$4.18B
| $19.6M | 3.08% |
474,503
-103,247
| -18% | -$4M |
2025 Q1
3 quarters
|
|
13
Biohaven
BHVN
$1.65B
| $14.1M | 2.21% |
+1,244,764
| New | +$15.4M |
2025 Q4
0 quarters
|
|
14
Structure Therapeutics
GPCR
$1.56B
| $14M | 2.2% |
+201,500
| New | +$8.23M |
2025 Q4
0 quarters
|
|
15
BioMarin Pharmaceuticals
BMRN
$10.7B
| $13.8M | 2.18% |
232,688
+7,574
| +3% | +$412K |
2025 Q1
3 quarters
|
|
16
Tyra Biosciences
TYRA
$1.29B
| $13.8M | 2.18% |
526,002
+11,055
| +2% | +$203K |
2024 Q1
7 quarters
|
|
17
BrightSpring Health Services
BTSG
$12.5B
| $11.5M | 1.81% |
+308,010
| New | +$10.3M |
2025 Q4
0 quarters
|
|
18
Centene
CNC
$34.7B
| $11.3M | 1.78% |
274,350
-113,250
| -29% | -$4.24M |
2025 Q2
2 quarters
|
|
19
Charles River Laboratories
CRL
$14.4B
| $11M | 1.73% |
+54,985
| New | +$9.97M |
2025 Q4
0 quarters
|
|
20
Teleflex
TFX
$5.22B
| $10.6M | 1.67% |
86,876
+46,819
| +117% | +$5.67M |
2025 Q3
1 quarter
|
|
21
Anteris Technologies
AVR
$610M
| $9.35M | 1.47% |
1,874,641
+102,040
| +6% | +$468K |
2024 Q4
4 quarters
|
|
22
Protara Therapeutics
TARA
$147M
| $9.14M | 1.44% |
+1,715,394
| New | +$9.54M |
2025 Q4
0 quarters
|
|
23
DELISTED
Cross Country Healthcare
CCRN
| $8.66M | 1.36% |
+1,068,821
| New | +$11.7M |
2025 Q4
0 quarters
|
|
24
Haemonetics
HAE
$5.51B
| $7.42M | 1.17% |
92,631
-105,404
| -53% | -$7.08M |
2025 Q3
1 quarter
|
|
25
ANI Pharmaceuticals
ANIP
$1.61B
| $6.89M | 1.08% |
87,272
+31,549
| +57% | +$2.73M |
2024 Q4
4 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, Sio Capital Management held 77 positions worth $636M, up 61% from $395M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Sio Capital Management deployed $141M of net new capital in Q4 2025, opening 26 new positions and adding to 8 existing holdings. Its largest new stake was Cigna: 172,203 shares worth $47.4M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 84% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Celcuity, an estimated $25.4M trimmed.
- Sio Capital Management's largest Q4 2025 buy was Cigna: 172,203 shares worth $47.4M.
- Sio Capital Management added most to Sanofi in Q4 2025, an estimated $20.3M increase.
- Sio Capital Management's biggest Q4 2025 reduction was Celcuity, cutting an estimated $25.4M.
- Sio Capital Management fully exited Merck in Q4 2025, selling an estimated $14.9M.
- Sio Capital Management's ten largest holdings make up 54% of its $636M portfolio in Q4 2025.
- Sio Capital Management opened 26 new positions and closed 9 in Q4 2025.
- Sio Capital Management's portfolio value rose 61% quarter-over-quarter to $636M.
Based on Sio Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.